Clinical Trials Directory

Trials / Completed

CompletedNCT05586919

Treatment of Venous Malformation

Treatment of Venous Malformation by Direct Puncture Repair: Ethanol Versus Polidocanol

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
20 (actual)
Sponsor
Al-Azhar University · Academic / Other
Sex
All
Age
18 Months – 36 Years
Healthy volunteers
Not accepted

Summary

Vascular malformations are birth defects that happen when different stages of angiogenesis shut down. 44 - 64% of all vascular malformations are venous malformations (VMs). Sclerotherapy is the first treatment line for VMs. It acts by getting rid of the vascular endothelial cells in the lesion. One of the most common and well researched sclerosing agents for VMs is polidocanol, which is a popular counterpart for concentrated ethanol.

Conditions

Interventions

TypeNameDescription
PROCEDUREDirect Puncture Repair / EthanolEthanol is an organic compound that will be injected in the venous malformation as a sclerotherapy by Direct Puncture Repair
PROCEDUREDirect Puncture Repair / PolidocanolPolidocanol is a sclerosing agent that will be injected in the venous malformation by Direct Puncture Repair

Timeline

Start date
2018-10-01
Primary completion
2021-01-01
Completion
2021-03-01
First posted
2022-10-19
Last updated
2022-10-19

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT05586919. Inclusion in this directory is not an endorsement.

Treatment of Venous Malformation (NCT05586919) · Clinical Trials Directory